

April 9, 2026



# Definium Therapeutics to Participate at Upcoming Investor Conferences and Events

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company's management team will participate in the following investor conferences and events:

- **25<sup>th</sup> Annual Needham Virtual Healthcare Conference**
  - Fireside Chat Date and Time: Thursday, April 16, 2026 at 3:00 PM EDT
  - Webcast Link: [25<sup>th</sup> Annual Needham Virtual Healthcare Conference](#)
- **Definium Therapeutics Investor & Analyst Day**
  - Date and Time: Wednesday, April 22, 2026 from 10:00 AM – 12:00 PM EDT (followed by lunch)
  - Location: Well& by Durst, 151 W 42nd St, New York, NY 10036
  - Registration Link (in person and virtual\*): [Definium Therapeutics Investor & Analyst Day](#)
  - \*In-person attendance is limited to invited research analysts and institutional investors.*
- **Needham Virtual Psychedelics Forum**
  - Panel: Clinical Risk, Regulatory Reality and the Path to Scale
  - Date and Time: Monday, April 27, 2026 at 11:00 AM EDT
  - Please contact your Needham representative for access to the panel presentation.*
- **2026 RBC Capital Markets Global Healthcare Conference**
  - Date and Time: Tuesday, May 19, 2026 at 8:00 AM EDT
  - Location: New York, NY
  - Webcast Link: [2026 RBC Capital Markets Global Healthcare Conference](#)

Audio webcasts and replays of available presentations will be accessible on Definium's [Investor Relations](#) website for up to 90 days following each event.

## About Definium Therapeutics

The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today's mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

For more information, visit <https://definiumtx.com/> and follow Definium Therapeutics on [Instagram](#), [LinkedIn](#) and [X](#).

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20260409979642/en/>

**Investor Contact:**

Gitanjali Jain

VP, Head of Investor Relations

[ir@definiumtx.com](mailto:ir@definiumtx.com)

**Media Contact:**

[media@definiumtx.com](mailto:media@definiumtx.com)

Source: Definium Therapeutics, Inc.